The association between albuminuria and thyroid antibodies in newly diagnosed type 2 diabetes mellitus patients with Hashimoto’s thyroiditis and euthyroidism

Wei Zhu 1,2, Xuejie Dong 2, Qingrong Pan 1, Yanjin Hu 1 and Guang Wang 1*

Abstract

Background: Microalbuminuria is a prognostic marker of diabetes kidney disease. It is generally diagnosed as the ratio of urinary albumin to creatinine (UACR) of 30-300 mg/g. Hashimoto’s thyroiditis is a common disease in the endocrinology and the thyroid antibodies may associated with kidney disease. We investigated the UACR in the newly diagnosed T2DM with Hashimoto’s thyroiditis and tried to detect the relationship between the UACR and thyroid antibodies.

Methods: One hundred twenty newly diagnosed T2DM patients with Hashimoto’s thyroiditis and euthyroidism and 50 sex and age-matched T2DM with non-Hashimoto’s and other thyroid disease were recruited. T2DM patients were divided into 2 groups by the titer of TPOAb: (1). TPOAb (+) group: T2DM with positive TPOAb (n = 105); (2). TPOAb (−) group: T2DM with negative TPOAb (n = 65).

Results: T2DM with positive TPOAb group had higher UACR than T2DM with negative TPOAb group (21.55 ± 7.28 vs 15.13 ± 5.69 mg/g, P < 0.01). UACR were positively related to BMI (r = 0.255, P < 0.05), FPG (r = 0.285, P < 0.05), HbA1c (r = 0.260, P < 0.05) and TPOAb (r = 0.349, P < 0.05). HbA1c (β = 0.793, P < 0.05), BMI (β = 0.342, P < 0.05) and lnTPOAb (β = 1.207, P < 0.05) were independently associated with UACR.

Conclusions: In the newly diagnosed T2DM patients, Hashimoto’s thyroiditis with TPOAb positive had higher UACR levels. TPOAb titer, BMI and HbA1c were independent associated with UACR in these patients.

Keywords: Type 2 diabetes mellitus, Hashimoto’s thyroiditis, Microalbuminuria

Background

Type 2 diabetes mellitus (T2DM) is an important public health problem in the world and 10.9% of the adult population in China was affected in 2013 [1]. Microalbuminuria is generally diagnosed as the ratio of urinary albumin to creatinine (UACR) of 30-300 mg/g or urine albumin excretion of 30-300 mg/24 h [2]. Microalbuminuria is a prognostic marker of diabetes kidney disease [3]. In addition, microalbuminuria increased the risk of cardiovascular morbidity and mortality, stroke, and heart failure. It begins even when the microalbuminuria is in normal range or high-normal range in both diabetes and euglycemic individuals [4–6]. For the diabetes patients, American diabetes association suggested that the urinary albumin should be assessed at least once per year [7].

Hashimoto’s thyroiditis is another common disease in the endocrinology. The morbidity of Hashimoto’s thyroiditis is 0.2% in men and 2% in women [8]. It is an
importance cause of hypothyroidism. The autoimmune mechanism of Hashimoto’s thyroiditis is associated to the renal disease. Some evidences point that about 10–30% Hashimoto’s thyroiditis patients had microprotei-
nuria or nephrotic syndrome [9]. The possible mechan-
ism is that thyroid antigens including thyroglobulin (TG) and thyroperoxidase (TPO) are released in the situ-
ation of Hashimoto’s thyroiditis. Both of TPO and TG can combine with their antibodies (TGAb and TPOAb) and form circulating immune complex. It can deposit in the glomerulus and as nephritis antigen to form in situ immune complex [10]. But whether Hashimoto’s thyroiditis aggravated the microalbuminuria in T2DM patients, the research is few. In this study, we tried to detect the association between the thyroid antibodies of Hashimoto’s thyroiditis and microalbuminuria in newly diagnosed T2DM with normal thyroid function patients.

Methods

Subjects

A total of 120 newly diagnosed T2DM patients with Hashi-
mo’to’s thyroiditis and euthyroidism and 50 newly diag-
nosed T2DM patients without Hashimoto’s and other thyroid disease were recruited in the outpatient endocrinology department of Beijing Chao-yang hospital from June 2015 to June 2018. Diagnostic criteria for Hashimoto’s thy-
roiditis were (1). The ultrasound tests showed thyroid par-
enchymal heterogeneity. (2). Elevated of thyroperoxidase antibody (TPOAb, >60 IU/ml) and/or thyroglobulin anti-
body (TGAb, >60 IU/ml). Diagnostic criteria of diabetes mellitus were according to the World Health Organization (WHO) criteria 2019. All patients should have the normal thyroid function. Their free T3 (FT3), free T4 (FT4), total T3 (TT3), total T4 (TT4) and thyroid-stimulating hormone (TSH) were in the normal range. All subjects were excluded if they had the history of other thyroid disease such as sub-
acute thyroiditis, Graves’ disease and thyroid carcinoma, type 1 diabetes mellitus and renal disease. Other diseases affecting microalbuminuria such as hypertension, systemic lupus erythematosus, gout and urinary tract infection were excluded. T2DM patients without thyroid disease should had euthyroidism and normal TPOAb and TGAb level.

T2DM patients were divided into 2 groups by the titer of TPOAb: (1). TPOAb (+) group: T2DM with positive TPOAb (n = 105); (2). TPOAb (−) group: T2DM with negative TPOAb (n = 65).

All patients enrolled in the study gave informed con-
sent. All procedures were conducted in accordance with Declaration of Helsinki. The ethics committee of Beijing Chao-yang Hospital approved the present research.

Laboratory measurements

All 170 patients underwent the assessment of the phys-
ica examination including height, weight and blood

pressure at the fasting state. Blood samples were col-
lected at morning fasting state. Test items included fast-
ing plasma glucose (FPG), Hba1c, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), triglycerides (TG), creatinine (Cr) and thyroid function (FT3, FT4, TT3, TT4, TSH), thyroid antibodies (TPOAb, TGAb). FT3, FT4, TT3, TT4, TSH, TPOAb and TGAb were measured by chemiluminescence. The normal ranges of thyroid parameters are listed below: FT3: 1.71–3.71 pg/ml; FT4: 0.7–1.48 ng/dl; TT3: 0.58–1.59 ng/ml; TT4: 4.87–11.72 μg/dl; TSH: 0.35–4.94 IU/ml; TPOAb: 0–60 IU/ml; TGAb: 0–60 IU/ml. Urinary albumin was tested using immunoturbidimetric assay. Urinary creatinine was enzymatically measured. Microalbuminuria was evaluated by the urinary albumin-to-creatinine ratio (UACR) in a random spot urine collection (mg/g). Thy-
roid ultrasound was performed in each subject. Body mass index (BMI) was calculated as height (kg)/

weight²(m²).

Statistical analysis

Data were analyzed by SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA). Continuous data as age, BMI, TC,
LDL-C, HDL-C, Cr, FT3, FT4, TT3, TT4, TSH, UACR,
systolic pressure (SBP) and diastolic pressure (DBP) were expressed as Mean ± SD. Normally distributed vari-
ables as TG, TPOAb, TGAb were expressed as median (IQR). Continuous data were analyzed by Student’s t test. Non-normally distributed variables were analyzed by nonparametric test. Pearson or Spearman’s rank cor-
relation was used to assess the association between UACR and other parameters. Multiple linear regres-
sions were used to assess the associated factors of UACR. TPOAb was In transformed before analysis. All analyses were two tailed and P < 0.05 were considered statistically significant.

Results

Baseline characteristics of the newly diagnosed T2DM patients with and without positive TPOAb

The baseline characteristics of newly diagnosed T2DM patients were performed in Table 1. The age, sex, BMI, blood pressure, TC, HDL-C, LDL-C, TG, FPG, Hba1c, Cr, TT3, TT4, FT3, FT4, TSH were matched in the two groups (Table 1).

The differences of UACR were summarized in Fig. 1. TPOAb positive group had higher UACR than TPOAb negative group (21.55 ± 7.28 vs 15.13 ± 5.69 mg/g, P < 0.01, Fig. 1).

The correlations between the UACR and other parameters

The correlation analyses were conducted to test the associations between UACR and other parameters
Table 1 Comparison of clinical parameters of T2DM with positive TPOAb and with negative TPOAb

| Parameter            | TPOAb (+) | TPOAb(−) | P Value |
|----------------------|-----------|-----------|---------|
| Age, years           | 46.9 ± 10.8 | 48.2 ± 10.5 | 0.429   |
| Sex, male/female     | 29/76     | 20/45     | 0.393   |
| BMI, kg/m²           | 27.45 ± 4.80 | 27.04 ± 4.67 | 0.590   |
| SBP: mmHg            | 115.9 ± 13.5 | 117.43 ± 13.23 | 0.466   |
| DBP: mmHg            | 75.2 ± 8.9  | 77.2 ± 9.3  | 0.151   |
| TC, mmol/L           | 5.30 ± 102  | 5.16 ± 123  | 0.451   |
| TG, mmol/L           | 3.07 ± 0.87 | 2.92 ± 0.80  | 0.258   |
| HDL-C, mmol/L        | 1.23 ± 0.35 | 1.18 ± 0.31  | 0.310   |
| TG, mmol/L           | 1.61 (1.06, 2.82) | 1.53 (1.09, 2.57) | 0.941   |
| Cr, μmol/L           | 69.80 ± 13.30 | 67.36 ± 12.96 | 0.661   |
| TGAB: IU/ml          | 426.19 (118.37, 621.80) | 22.74 (8.29, 47.84) | < 0.001 |
| TT3: ug/dl           | 0.96 ± 0.21 | 1.02 ± 0.23  | 0.069   |
| TT4: ug/dl           | 6.33 ± 1.33 | 6.71 ± 1.60  | 0.095   |
| FT3: pg/ml           | 2.52 ± 0.43 | 2.64 ± 0.48  | 0.090   |
| FT4: ng/dl           | 1.10 ± 0.16 | 1.15 ± 0.23  | 0.133   |
| TSH: Uiu/ml          | 2.06 ± 1.25 | 2.09 ± 0.84  | 0.869   |
| UACR: IU/ml          | 264.19 (118.37, 621.80) | 22.74 (8.29, 33.43) | < 0.001 |
| TGAB: IU/ml          | 71.55 (24.25, 188.74) | 20.04 (8.97, 47.84) | < 0.001 |

Abbreviations: BMI body mass index; SBP systolic pressure; DBP diastolic pressure; TC total cholesterol; LDL-C low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; TG triglycerides; Cr creatinine; TT3 total T3; TT4 total T4; FT3 free T3; FT4 free T4; TSH thyroid stimulating hormone; TPOAb thyroperoxidase antibody; TGAb thyroglobulin antibody

Multiple regressions of UACR and its related factors
Table 2 showed the multiple regressions of various independent variables to test the association with UACR. HbA1c, BMI and TPOAb were entered in the regression model. TPOAb was Ln transformed before analysis. Multiple regression analysis demonstrated that HbA1c (β = 0.793, P < 0.05), BMI (β = 0.342, P < 0.05) and ln TPOAb (β = 0.1207, P < 0.05) were independently associated with UACR.

Discussion
UACR is the ratio of urinary albumin and creatinine. It represents the microalbuminuria in the T2DM. UACR is not only the important marker of diabetes kidney disease with diabetes kidney disease which occurs in nearly 20–40% of diabetes patients, but also the predictor of some complications of T2DM such as cardiovascular disease and stroke and so on [5]. In the previous studies, the morbidity and mortality of cardiovascular was positively associated with UACR, although the UACR is in the normal range [5, 11]. These effects even happen in the non-diabetes [4]. In our research, the UACR of newly diagnosed T2DM patients was positively related to the fasting plasma glucose and HbA1c. In the research of diabetes, there is a clear relationship between the microalbuminuria and glycemic control. Intensive glycemic control has been shown in many studies to delay the onset and progression of albuminuria in both type 1 and type 2 diabetes mellitus [12, 13]. Our findings were consistent with those previous studies.

The main finding of our research is the relationship between the TPOAb and albuminuria in newly diagnosed T2DM patients. In our research, T2DM with TPOAb positive patients had higher albuminuria than TPOAb negative patients. In the correlated and regression analysis, TPOAb seem to be the main factor related to the albuminuria in T2DM patients. In the previous studies, thyroid function is closely related to the albuminuria in T2DM patients. The relationships of UACR and other parameters as age, sex, SBP, DBP, TC, LDL-C, HDL-C, TG, TT3, TT4, FT3, FT4, TSH, TGAb were not statistically significant (P>0.05).
thyroiditis might be accompanied with proteinuria [16]. Some researchers found that TPO and TG in the subepithelial immune deposit and mediated immune complex glomerulonephritis. Both of TPO and TG can be trapped in subendothelial level and elevated glomerular permeability [17]. In addition, Guangda Xiang’s research demonstrated that Hashimoto’s thyroiditis patients had endothelial serious dysfunction even in the stage of euthyroidism. Endothelial dysfunction is associated with albuminuria [18].

In the histopathology research both TPOAb and TGAb can be trapped at subendothelial level. But in our research, we found TPOAb was the independent influence factor of UACR but not TGAb. In addition, the differences of TPOAb and TGAb are in the complement system and cytotoxicity. TPOAb could induce the complement system and cellular cytotoxicity in contrast to TGAb. The effects lead to the aggravation of inflammatory status [19]. It may result in the higher UACR level in the T2DM patients.

The present research also found that BMI is the independently associated with UACR. This is consistent with many previous studies. Obesity especially visceral obesity is the important risk factor of diabetes kidney disease [20, 21]. One possible hypothesis is obesity-induced glomerular hyperfiltration and increased urinary albumin excretion rate [22]. Moreover, adipocyte secrete inflammatory factors such as TNF-α and C-reactive protein. These factors are toxic to glomerular podocytes and mesangial cells [23, 24]. Other mechanisms include insulin resistance, excessive lipid deposition oxidative stress caused by obesity [25, 26].

Some limitations of the present study must be mentioned. First, the sample size of Hashimoto’s thyroiditis patients with T2DM was small. Second, the diagnosis of Hashimoto’s thyroiditis accorded to the TPOAb, TGAb and ultrasound test. Pathological biopsy might make the diagnosed of Hashimoto’s thyroiditis more accurate. Finally, the UACR is influenced by many factors such as

![Fig. 2](image)

**Fig. 2** UACR were positively related to the BMI ($r = 0.255, P < 0.05$, a, FPG ($r = 0.285, P < 0.05$, b, HbA1c ($r = 0.260, P < 0.05$, c and TPOAb ($r = 0.349, P < 0.05$, d. Abbreviations: UACR: ratio of urinary albumin and creatinine; BMI: body mass index; FPG: fasting plasma glucose; TPOAb: thyroid peroxidase antibody; TGAb: thyroglobulin antibody

| Parameters         | $B$   | $SE$   | $P$ value |
|--------------------|-------|--------|-----------|
| BMI, kg/m²         | 0.342 | 0.112  | 0.003     |
| HbA1C, %           | 0.793 | 0.313  | 0.014     |
| Ln-TPOAb, IU/ml    | 1.207 | 0.287  | <0.001    |

Abbreviations: BMI body mass index; TPOAb thyroperoxidase antibody
Conclusions
In the newly diagnosed T2DM patients, Hashimoto’s thyroiditis with TPOAb positive had higher UACR levels. TPOAb titer, BMI and HbA1c independent associated with UACR in these patients.

Abbreviations
T2DM: Type 2 diabetes mellitus; TPOAb: Thyroperoxidase antibody; TGAb: Thyroglobulin antibody; UACR: Ratio of urinary albumin and creatinine; BMI: Body mass index; WHO: World Health Organization; FT3: Free T3; FT4: Free T4; T3T: Total T3; T4T: Total T4; TSH: Thyroid-stimulating hormone; FPG: Fasting plasma glucose; TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; TG: Triglycerides

Acknowledgements

Authors’ contributions
GW designed the study. WZ and XJD collected the clinical data. WZ and XJD conducted the statistical analysis. WZ wrote the manuscript. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All subjects gave their written informed consent. All procedures followed the ethical standards of the responsible committee of Beijing Chao-yang Hospital approved the present research.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interest.

Author details
1Department of Endocrinology, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, People’s Republic of China. 2Department of Endocrinology, Beijing Aerospace General Hospital, Beijing 100076, People’s Republic of China.

Received: 30 April 2020 Accepted: 13 November 2020
Published online: 23 November 2020

References
1. Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and Prediabetes in China in 2013. JAMA. 2017;317(24):2515–23.
2. de Zeeuw D. Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin Nephrol. 2007;27(2):172–81.
3. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–83.
4. Tanaka F, Komi R, Makita S, et al. Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in non-diabetic and normotensive individuals. J Hypertens. 2016;34(3):506–12.
5. Pan Q, Xu Y, Yang N, et al. Metformin or Acarbose treatment significantly reduced albuminuria in patients with newly diagnosed type 2 diabetes mellitus and low-grade albuminuria. Med Sci Monit. 2018;24:8941–9.
6. Elías S, Ganza-Arnedillo A, Sánchez-Monedero M, et al. Microalbuminuria could improve risk stratification in patients with T2D and minor stroke. Ann Clin Transl Neurol. 2016;3(9):678–83.
7. Association AD. Improving care and promoting health in populations: standards of medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):57–513.
8. Benveniga S, Tramarchi F. Changing presentation of Hashimoto’s thyroiditis in north-eastern Sicily and Calabria (southern Italy) based on a 31-year experience. Thyroid. 2008;18(4):429–41.
9. Ronco P, Debiec H. Pathophysiological lessons from rare associations of immunological disorders. Pediatr Nephrol. 2009;24(1):3–8.
10. Jordan SC, Buckingham B, Sakai R, et al. Studies of immune-complex glomerulonephritis mediated by human thyroglobulin. N Engl J Med. 1981;304(20):1212–5.
11. Hong JW, Ku CR, Noh JH, et al. Association between low-grade albuminuria and cardiovascular risk in Korean adults: the 2011-2012 Korea National Health and nutrition examination survey. PloS One. 2015 Mar 5(10):e011866.
12. DCCT/EDIC research group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the diabetes control and complications trial and epidemiology of diabetes interventions and complications study. Lancet Diabetes Endocrinol. 2014;2(10):793–800.
13. Levin SR, Cobum JW, Abraira C, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans affairs cooperative study group on glycemic control and complications in type 2 diabetes feasibility trial investigators. Diabetes Care. 2002;25(10):1478–85.
14. Iglesias P, Bajo MA, Selgas R, et al. Thyroid dysfunction and kidney disease: an update. Rev Endocr Metab Disord. 2017;18(1):131–44.
15. Xie J, Wang X, Zhang Y, et al. The longitudinal effect of subclinical hyperthyroidism on urine microalbumin-to-urine creatinine ratio in patients with type 2 diabetes mellitus. BMC Endocr Disord. 2019;19(1):84.
16. O’Regan S, Fong J, Kaplan BS, et al. Thyroid antigen-antibody niptosis. Clin Immunol Immunopathol. 1976;6(3):341–4.
17. Santoro D, Vadalà C, Siligato R, et al. Autoimmune Thyroiditis and Glomerulopathies. Front Endocrinol (Lausanne). 2017;8:119.
18. Xiang GD, He YS, Zhao LS, et al. Impairment of endothelium-dependent arterial dilation in Hashimoto’s thyroiditis patients with euthyroidism. Clin Endocrinol. 2006;64(6):698–702.
19. Mikołajski M, Mikołaj M, Obasa-Mozytńska M, Niedziela M. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol. 2014;65(2):150–5.
20. Man REK, Gan ATL, Fenwick EK, et al. The Relationship between Generalized and Abdominal Obesity with Diabetic Kidney Disease in Type 2 Diabetes: A Multiethnic Asian Study and Meta-Analysis. Nutrients. 2018;10(11):E1685.
21. Belhatem N, Mohammadi K, Rouzet F, et al. Impact of morbid obesity on the kidney function of patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;108(1):143–9.
22. Marek-Bilkan C. Obesity and diabetic kidney disease. Med Clin North Am. 2013;97(1):59–74.
23. Gao L, Boston A, Jegede O, et al. Inflammation and kidney injury in diabetic African American men. J Diabetes Res. 2019;2019:5359635.
24. Fathy SA, Mohamed MR, Ali MAM, et al. Influence of IL-6, IL-10, INF-γ and TNF-α genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients. Biomarkers. 2019;24(1):43–55.
25. Whaley-Connell A, Sowers JR. Insulin resistance in kidney disease: is there a distinct role separate from that of diabetes or obesity? Cardiovasc Med. 2017;8(1):41–9.
26. Martínez-García C, Izquierdo-Lahuerta A, Vivas Y, et al. Renal lipotoxicity-associated inflammation and insulin resistance affects actin cytoskeleton Organization in Podocytes. PloS One. 2015;10(11):e0142291.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.